Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period

dc.creatorFlorentino, Pilar T. V
dc.creatorAlves, Flávia J. O
dc.creatorSilva, Thiago Cerqueira
dc.creatorOliveira, Vinicius de Araújo
dc.creatorJúnior, Juracy B. S.
dc.creatorJantsch, Adelson G
dc.creatorPenna, Gerson O
dc.creatorBoaventura, Viviane
dc.creatorWerneck, Guilherme L
dc.creatorRodrigues, Laura C
dc.creatorPearce, Neil
dc.creatorBarral Netto, Manoel
dc.creatorBarreto, Mauricio L
dc.creatorPaixão, Enny S
dc.date2022-10-11T17:49:17Z
dc.date2022-10-11T17:49:17Z
dc.date2022
dc.date.accessioned2023-09-27T00:14:38Z
dc.date.available2023-09-27T00:14:38Z
dc.identifierFLORENTINO, Pilar T. V. et al. Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period. Nature Communications, v. 13, n.1, p. 1-5, 2022.
dc.identifier2041-1723
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/55112
dc.identifier10.1038/s41467-022-32524-5
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8898886
dc.descriptionFundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro. Wellcome Trust. "Fazer o bem faz bem” program. Brazilian National Research Council.
dc.descriptionAlthough severe COVID-19 in children is rare, they may develop multisystem inflammatory syndrome, long-COVID and downstream effects of COVID-19, including social isolation and disruption of education. Data on the effectiveness of the CoronaVac vaccine is scarce during the Omicron period. In Brazil, children between 6 to 11 years are eligible to receive the CoronaVac vaccine. We conducted a test-negative design to estimate vaccine effectiveness using 197,958 tests from January 21, 2022, to April 15, 2022, during the Omicron dominant period in Brazil among children aged 6 to 11 years. The estimated vaccine effectiveness for symptomatic infection was 39.8% (95% CI 33.7-45.4) at ≥14 days post-second dose. For hospital admission vaccine effectiveness was 59.2% (95% CI 11.3-84.5) at ≥14 days. Two doses of CoronaVac in children during the Omicron period showed low levels of protection against symptomatic infection, and modest levels against severe illness.
dc.formatapplication/pdf
dc.languageeng
dc.publisherNature Research
dc.rightsopen access
dc.subjectCOVID-19
dc.subjectCriança
dc.subjectIsolamento social
dc.subjectvacina
dc.subjectCOVID-19
dc.subjectChild
dc.subjectSocial isolation
dc.subjectVaccine
dc.titleVaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period
dc.typeArticle


Este ítem pertenece a la siguiente institución